Incorporating lipoprotein (a) into patient care: Polish landscape in light of national recommendations and the updated ESC/EAS guidelines
Open Access
- 20 October 2025
- journal article
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (6) , 2246-2257
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in Poland. Lipoprotein (a) [Lp(a)] constitutes an independent, causal risk factor for ASCVD and aortic valve stenosis. Elevated Lp(a) is found in approximately 20% of the Polish population. Lp(a) measurements have been recommended in all adult patients to improve cardiovascular risk stratification. As the testing rate remains insufficient, there is a need to facilitate the incorporation of Lp(a) into routine patient care. This clinically oriented review outlines (i) up-to-date evidence on the role of Lp(a) in cardiovascular diseases, (ii) recent real-world data on the characteristics of Polish patients with elevated Lp(a), and (iii) strategies for Lp(a) testing and management in light of the current national recommendations and the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias.Keywords
This publication has 94 references indexed in Scilit:
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular riskAtherosclerosis, 2019
- Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassaysAtherosclerosis, 2019
- High lipoprotein(a) and high risk of mortalityEuropean Heart Journal, 2019
- A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoformsJournal of Lipid Research, 2017
- A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reductionEuropean Heart Journal, 2017
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trialsThe Lancet, 2016
- Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General PopulationJACC, 2014
- Genetic Associations with Valvular Calcification and Aortic StenosisNew England Journal of Medicine, 2013
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary DiseaseNew England Journal of Medicine, 2009
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial InfarctionJAMA, 2009